Position of the Transparency Council – Revestive (teduglutide)
At its meeting on 23 December 2024, the Transparency Council adopted position No. 157/2024 on the appropriateness of issuing approvals for reimbursement of the drug Revestive (teduglutide) for the indication: short bowel syndrome